< 生产厂家价格 >

雷尼替丁-S-氧化物

雷尼替丁-S-氧化物用途

雷尼替丁S-氧化物是雷尼替汀(HY-B0693)的代谢物。雷尼替丁是一种有效、选择性和口服活性组胺H2受体拮抗剂,IC50为3.3μM,可抑制胃分泌[1][2]。

点击显示

雷尼替丁-S-氧化物名称

[ CAS 号 ]:
73851-70-4

[ 中文名 ]:
雷尼替丁-S-氧化物

[ 英文名 ]:
Ranitidine S-Oxide

[英文别名 ]:

Ranitidine Impurity 3

雷尼替丁-S-氧化物生物活性

[ 描述 ]:

雷尼替丁S-氧化物是雷尼替汀(HY-B0693)的代谢物。雷尼替丁是一种有效、选择性和口服活性组胺H2受体拮抗剂,IC50为3.3μM,可抑制胃分泌[1][2]。

[ 相关类别 ]:

研究领域 >> 代谢疾病

[参考文献]

[1]. Cross DM, et al. Kinetics of ranitidine metabolism in dog and rat isolated hepatocytes. Xenobiotica. 1995 Apr;25(4):367-75.

[2]. Leucuta A, et al. A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine. Drug Metabol Drug Interact. 2004;20(4):273-81.

雷尼替丁-S-氧化物物理化学性质

[ 密度 ]:
1.265g/cm3

[ 沸点 ]:
527.5ºC at 760 mmHg

[ 分子式 ]:
C₁₃H₂₂N₄O₄S

[ 分子量 ]:
330.40300

[ 闪点 ]:
272.8ºC

[ 精确质量 ]:
330.13600

[ PSA ]:
122.54000

[ LogP ]:
2.64520

[ 折射率 ]:
1.577

[ 储存条件 ]:
Hygroscopic, -20°C Freezer, Under Inert Atmosphere

雷尼替丁-S-氧化物MSDS

详细MSDS(安全技术说明书)

雷尼替丁-S-氧化物安全信息

[ 符号 ]:

GHS07, GHS08

[ 信号词 ]:
Danger

[ 危害声明 ]:
H317-H334-H335

[ 警示性声明 ]:
P261-P280-P342 + P311

[ 危害码 (欧洲) ]:
Xn

[ 风险声明 (欧洲) ]:
37-42/43

[ 安全声明 (欧洲) ]:
22-36/37

[ 危险品运输编码 ]:
NONH for all modes of transport

雷尼替丁-S-氧化物文献

Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FM03 gene mutations in a Korean population.

Pharmacogenetics 10(1) , 67-78, (2000)

A non-invasive urine analysis method to determine the in-vivo flavin-containing mono-oxygenase (FMO) activity catalysing N-oxidation of ranitidine (RA) was developed and used to phenotype a Korean pop...

Qualitative and quantitative analysis of ranitidine and its metabolites by high-performance liquid chromatography-mass spectrometry.

J. Chromatogr. A. 323(1) , 143-52, (1985)

Reversed-phase high-performance liquid chromatography systems for the separation of ranitidine and its metabolites ranitidine-N-oxide, ranitidine-S-oxide, and desmethylranitidine have been developed f...

Sulphoxidation and sulphation capacity in patients with primary biliary cirrhosis.

J. Hepatol. 22(5) , 551-60, (1995)

We have previously reported an association of impaired S-oxidation with primary biliary cirrhosis. In order to confirm and further define this relationship, we retested S-oxidation capacity via three ...

更多文献